Students

6th National Course on Sleep Medicine

admin — Thu, 12 Dec 2024 14:46:27 +0000

This two-day training course is designed to provide and enhance a basic working knowledge of sleep medicine.

2025 Hughlings Jackson Lecture: The Basal Ganglia and the Motivation to Act

admin — Mon, 13 Jan 2025 21:40:52 +0000

Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honours the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the development of neurology as a medical specialty.

8th National Neuromuscular Review Course

admin — Thu, 13 Feb 2025 16:08:29 +0000

Dr. Nicolas Dupré of Laval University, Dr. Karine Garneau of Université de Montréal, and the members of the organizing committee are pleased to announce the 8th National Neuromuscular Review Course.

Six principal investigators from The Neuro receive CIHR grants

admin — Mon, 10 Feb 2025 18:44:57 +0000

Projects include important research on Parkinson’s, glioblastoma and dementia

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

admin — Fri, 14 Mar 2025 13:09:39 +0000

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

AI analysis of healthcare records reveals key factors in autism diagnosis

admin — Wed, 26 Mar 2025 15:23:21 +0000

Scientists argue the criteria we use for diagnosing autism may need revision

Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Latest Alzheimer’s drug shown less effective in females than males

admin — Tue, 18 Mar 2025 18:27:46 +0000

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Prescribing anti-swelling drug reduces immune response weeks after last dose

admin — Wed, 26 Feb 2025 16:05:58 +0000

Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy

Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body’s ability to fight the cancer.

Expanding access to specialized healthcare across Quebec: ECHO Superhub at The Neuro

admin — Tue, 25 Mar 2025 18:37:02 +0000

Free, online training program strengthens training and brings specialized care to communities across Quebec

A healthcare telementoring program housed at The Neuro and supported by the Transforming Autism Care Consortium (TACC) is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

Project to create AI model for ALS receives Génome Québec funding

admin — Mon, 17 Mar 2025 15:29:17 +0000

$400,000 will fuel public-private collaboration to discover new disease biomarkers

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

D2R awards $10 million to accelerate RNA-based therapies for rare diseases and cancer

admin — Wed, 26 Mar 2025 11:03:15 +0000

Montreal, March 26, 2025 – 51�Թ��’s DNA to RNA Initiative (D2R) has awarded over $10 million in funding to support three groundbreaking research projects that will advance RNA-based therapies for cancer and rare genetic diseases. The awards were initially announced at the D2R Research Symposium on March 13, 2025.

Genetic sequencing project receives more than $8 million in funding

admin — Tue, 18 Mar 2025 14:55:14 +0000

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 51�Թ�� and Martine Tétreault, PhD, at Université de Montréal has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Call for Abstracts - MUHC Mental Health Mission Research Day

admin — Fri, 04 Apr 2025 20:17:55 +0000

The 3rd Annual MUHC Mental Health Mission Research Day will be held at the South Seminar Room (P1.082) of the Allen Memorial Institute and via zoom on Friday April 25, 20205. This year’s program will feature individual research talks and a poster session. Poster abstract submissions will be accepted until Friday April 14th at 5:00 pm. More information

Dre Cécile Rousseau, 98.5FM

admin — Wed, 22 Jan 2025 19:36:37 +0000

Tendance chez les jeunes - Diversité : « Il y a un prix à censurer les désaccords et les malaises ». Écoutez ici

Dr. Simon Ducharme, Montreal General Hospital Foundation

admin — Fri, 28 Feb 2025 13:59:57 +0000

Taking the Pulse: What is Precision Psychiatry. Listen here